Dr. Tony Holohan:

I must make the point for general understanding that screening is focussed on the type responsible for 90% of cases. In a case where a person goes on to have an invasive cancer of the other type, previous knowledge of the screening history has no value and a decision may be made at that point that there would be no need to pass that information. That is a matter on which an individual clinician can make a decision.